@article{TCR32519,
author = {De-Jian Ma and Zeng-Jun Li and Xi-Yan Wang and Xian-Jun Zhu and Yan-Lai Sun},
title = {Octreotide treatment of cancer chemoradiotherapy-induced diarrhoea: a meta-analysis of randomized controlled trials},
journal = {Translational Cancer Research},
volume = {8},
number = {6},
year = {2019},
keywords = {},
abstract = {Background: Patients receiving radiotherapy and chemotherapy have a high risk developing to an acute chemoradiotherapy-induced diarrhea (RID). The clinical efficacy of octreotide in controlling chemoradiotherapy-induced diarrhea remains controversial. We performed a meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy of octreotide for treatment the chemoradiotherapy-induced diarrhoea.
Methods: Relevant RCTs studies assessing the effect of octreotide on clinical outcomes compared with placebo were searched in Cochrane Library, PubMed, EMBASE and Web of Science (up to December 2018). Heterogeneity was assessed with I2, and publication bias was evaluated using sensitive analysis.
Results: Eight trials, a total of 594 participants. We found octreotide was significantly effective compared with the control group (OR =3.17; 95% CI, 1.28–7.85; P},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/32519}
}